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Comparison of the effectiveness 
of Martin’s equation, Friedewald’s 
equation, and a Novel equation 
in low‑density lipoprotein 
cholesterol estimation
Youhyun Song1,12, Hye Sun Lee2,12, Su Jung Baik3, Soyoung Jeon2, Donghee Han4, 
Su‑Yeon Choi5, Eun Ju Chun6, Hae‑Won Han7, Sung Hak Park8, Jidong Sung9, Hae Ok Jung10, 
Ji Won Lee1* & Hyuk‑Jae Chang11*
Low‑density‑lipoprotein cholesterol (LDL‑C) is the main target in atherosclerotic cardiovascular 
disease (ASCVD). We aimed to validate and compare a new LDL‑C estimation equation with other 
well‑known equations. 177,111 samples were analysed from two contemporary population‑based 
cohorts comprising asymptomatic Korean adults who underwent medical examinations. Performances 
of the Friedewald (FLDL), Martin (MLDL), and Sampson (SLDL) equations in estimating direct LDL‑C 
by homogenous assay were assessed by measures of concordance  (R2, RMSE, and mean absolute 
difference). Analyses were performed according to various triglyceride (TG) and/or LDL‑C strata. 
Secondary analyses were conducted within dyslipidaemia populations of each database. MLDL 
was superior or at least similar to other equations regardless of TG/LDL‑C, in both the general and 
dyslipidaemia populations (RMSE = 11.45/9.20 mg/dL;  R2 = 0.88/0.91; vs FLDL: RMSE = 13.66/10.42 mg/
dL;  R2 = 0.82/0.89; vs SLDL: RMSE = 12.36/9.39 mg/dL;  R2 = 0.85/0.91, per Gangnam Severance Hospital 
Check‑up/Korea Initiatives on Coronary Artery Calcification data). MLDL had a slight advantage over 
SLDL with the lowest MADs across the full spectrum of TG levels, whether divided into severe hyper/
non‑hyper to moderate hypertriglyceridaemia samples or stratified by 100‑mg/dL TG intervals, even 
up to TG values of 500–600 mg/dL. MLDL may be a readily adoptable and cost‑effective alternative to 
direct LDL‑C measurement, irrespective of dyslipidaemia status. In populations with relatively high 
prevalence of mild‑to‑moderate hypertriglyceridaemia, Martin’s equation may be optimal for LDL‑C 
and ASCVD risk estimation.
Low-density lipoprotein cholesterol (LDL-C) is a primary therapeutic target in the prevention of cardiovascular 
disease (CVD). In a previous meta-analysis, the relative risk of major vascular events was proportionally reduced 
even at normal LDL-C levels and each 39-mg/dL reduction in this level reduced the risk of cardiovascular 
OPEN
1Department of Family Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju‐
ro, Gangnam‐gu, Seoul 06273, Korea. 2Biostatistics Collaboration Unit, Yonsei University College of Medicine, 211 
Eonju-ro, Gangnam-gu, Seoul 06273, Korea. 3Healthcare Research Team, Health Promotion Center, Gangnam 
Severance Hospital, 211 Eunju-ro, Gangnam-gu, Seoul 06273, Korea. 4Department of Imaging and Medicine, 
Cedars Sinai Medical Center, Los Angeles, CA, USA. 5Division of Cardiology, Seoul National University Healthcare 
System Gangnam Center, Seoul National University College of Medicine, Seoul, Korea. 6Department of Radiology, 
Seoul National University Bundang Hospital, Seoul, Korea. 7Department of Internal Medicine, Gangnam Heartscan 
Clinic, Seoul, Korea. 8Department of Radiology, Gangnam Heartscan Clinic, Seoul, Korea. 9Division of Cardiology, 
Department of Medicine, Sungkyunkwan University School of Medicine, Heart Stroke & Vascular Institute, 
Samsung Medical Center, Seoul, Korea. 10Division of Cardiology, Cardiovascular Center, College of Medicine, 
Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea. 11Division of Cardiology, Severance 
Cardiovascular Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, 




Scientific Reports |        (2021) 11:13545  | https://doi.org/10.1038/s41598-021-92625-x
www.nature.com/scientificreports/
events by about a  fifth1. Recent American Heart Association/American College of Cardiology (AHA/ACC) and 
European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines emphasise the use of 
aggressive LDL-C targeted therapy for reductions in the level of LDL-C by > 50% if the level is higher than a 
certain threshold in very high-risk  patients2–4. Therefore, accurate LDL-C measurement is important in therapy-
related decision-making and planning in clinical practice.
Several equations for LDL-C estimation are generally utilised when direct measurement is unavailable or 
 expensive5. Traditionally, LDL-C is widely estimated using the Friedewald equation (FLDL). However, this equa-
tion is associated with very low-density lipoprotein cholesterol (VLDL-C) overestimation and LDL-C under-
estimation under conditions of low LDL-C and high triglyceride (TG) levels, given the fixed TG:VLDL-C ratio 
of 5:16,7. Inaccurate LDL-C estimation may lead to cardiovascular risk misclassification. Therefore, Martin et al. 
developed an equation using an adjustable factor (strata-specific median VLDL-C:TG ratio) in place of the fixed 
TG denominator of  58. This equation is more accurate than the Friedewald equation, particularly at low LDL-C 
levels, and shows a much stronger concordance with directly measured LDL-C using the ultracentrifugation 
method than the Friedewald equation, according to TG  level9. Nonetheless, the Martin/Hopkins LDL-C (MLDL) 
equation (or Martin’s equation) does still tend to overestimate the LDL-C level (or direct LDL-C [dLDL]) at high 
TG concentrations.
Recently, Sampson et al. derived a novel LDL-C (SLDL) equation using the United States (US) National Insti-
tutes of Health database, including 18,715 samples from 8656 patients. The new equation, which they deemed 
particularly favourable for use in patients with low levels of LDL-C and/or hypertriglyceridemia, yielded a 
misclassification rate lower than 35% in the categorisation of patients with hypertriglyceridemia into different 
LDL-C treatment  groups5.
For the adoption of new methods, the principles of evidence-based medicine require external validation in 
independent populations on the basis of various race/ethnicities and the use of other laboratory techniques. To 
the best of our knowledge, no study till date has validated the Sampson equation in Asian populations. Accord-
ingly, this study aimed to validate and compare the performance of the Friedewald, Martin, and Sampson equa-
tions in LDL-C estimation with a direct homogeneous assay in the Korean population.
Methods
Study population. This study used data from two large population-based databases: the Gangnam Sever-
ance Hospital Health Promotion Center Cohort (Gangnam Severance Hospital Check-up [GSHC]) and the 
Korea Initiatives on Coronary Artery Calcification (KOICA) registry. A total of 79,467 individuals (Korean 
adults aged ≥ 19 years) underwent in-depth medical examinations in the Gangnam Severance Hospital between 
2nd March 2007 and 12th March 2020; this database comprises 144,910 samples. The retrospective, multicentre, 
observational KOICA registry was designed for the evaluation of the value of coronary artery calcification scores 
in the prediction of CVD in asymptomatic Korean adults. A total of 48,901 participants were initially enrolled 
between December 2002 and July 2014; the database comprises 56,446 samples. Details on the  GSHC10 and 
 KOICA11 have been provided elsewhere. The populations of both databases comprise self-referred individuals 
who underwent general health check-ups at healthcare centres in Seoul, South Korea, and information on their 
personal medical history and data were obtained by self-reported questionnaires. All participants voluntarily 
signed an informed consent form before the study, and the institutional review boards (IRB) of each study site 
approved the study protocols.
After excluding samples with missing lipid values, a total of 177,111 samples were included—129,985 cases 
from the GSHC and 47,126 cases from the KOICA. Figure 1 presents a flow chart of the study process. Second-
ary analyses were performed in the subgroups of participants who met the diagnostic criteria for dyslipidaemia 
in each database (53,036 cases from the GSHC and 25,265 from the KOICA) for the additional validation and 
comparison of the three equations in individuals with dyslipidaemia. Additional sensitivity analyses were per-
formed after exclusion of the highest and lowest 0.5 percentiles of each lipid parameter (total cholesterol [TC], 
high-density lipoprotein cholesterol [HDL-C], TG, non-HDL-C, and LDL-C) (See Supplementary File 2 for full 
results). This study was conducted in accordance with the Declaration of Helsinki and approved by the Institu-
tional Review Board of Severance Hospital (IRB No: 4-2020-0323).
LDL‑C estimation. The level of LDL-C was estimated using the Friedewald, Martin, and Sampson equa-
tions, which are:
Definition of dyslipidaemia. Dyslipidaemia was defined on the basis of the presence of a diagnosis by a 
physician, the current use of lipid-lowering medications, or National Cholesterol Education Program (NCEP)—
Adult Treatment Panel III criteria: (1) hypercholesterolaemia (serum TC ≥ 240 mg/dL), (2) hypertriglyceridemia 
(serum TG ≥ 150 mg/dL), (3) hyper-LDL-cholesterolaemia (serum LDL-C ≥ 160 mg/dL), or (4) hypo-HDL-cho-
lesterolaemia (serum HDL-C < 40 mg/dL).
Friedewald equation : LDL− C = TC−HDL− C− TG/5
Martin equation: LDL− C =TC−HDL− C− TG/adjustable factor (based on the non - HDL - C and
TG levels derived from a 180− cell 2D table)
Sampson equation : LDL - C = TC/0.948−HDL - C/0.971−
(
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Lipid measurements. Blood samples were collected after an eight-hour fast, at minimum, in both cohorts. 
In the GSHC, serum LDL-C was measured by a homogenous direct assay using reagents from Sekisui Medical 
Corporation (Tokyo, Japan) on a Hitachi 7600 automated analyser (Hitachi, Tokyo, Japan) until 17th March 
2014 and then by a homogeneous direct assay using reagents from Beckman Coulter Inc. (Brea, CA, USA) on an 
AU5800 automated analyser (Beckman Coulter Inc.) from 18th March 2014. In the KOICA registry, data were 
gathered from three locations: Severance Check-up Healthcare Center, Seoul National University Healthcare 
System Gangnam Center, and Samsung Medical Center. Serum LDL-C levels were measured by homogenous 
direct assays using reagents from Sekisui, Beckman, or Roche Diagnostics (Mannheim, Germany) on Hitachi 
7600, Modular D2400, or Architect Ci8200 (Abbott, Abbott Park, IL) automated analysers. Further details of 
lipid measurements are shown in Supplementary Table S4 (File 1).
The departments of laboratory medicine at all the sites have been accredited by the Korean Society of Lab-
oratory Medicine and participate in annual inspections administered by the Korean Association of Quality 
Assurance for Clinical Laboratories as well as Proficiency Testing surveys provided by the College of American 
Pathologists.
Statistical analysis. Continuous variables are reported as mean (standard deviation), median (interquar-
tile range [IQR]), and range. Categorical variables are shown as number (%).
The relationships between the three equations and dLDL were visually assessed with scatter plots, and the 
formulae were derived by linear regression. Concordance was evaluated with  R2 and root mean square error 
(RMSE). The difference between the dLDL and LDL-C estimations obtained according to high/low TG or LDL-C 
levels, stratified by TG or LDL-C levels across the ranges of each value were used to draw residual error plots, 
following which mean absolute difference (MAD) values were evaluated.
All analyses were performed using data on both the general and dyslipidaemia populations with SAS 9.2 (SAS 
Institute, Cary, NC). Two-sided P values < 0.05 were considered statistically significant.
Results
The distribution of lipid values of the patients (from both the general and dyslipidaemia populations) in the 
GSHC and KOICA databases are presented in Table 1. A total of 129,985 samples were included in the GSHC 
database (53.53% male; age 48.58 [11.46] years) and 47,126 in the KOICA database (76.04% male; age 54.05 
[8.88] years); the prevalence rates of dyslipidaemia were 53,036 (40.80%) and 25,265 (53.61%), respectively. In 
the GSHC (ranges, TG: 8–3271 mg/dL; LDL-C: 10–386 mg/dL), 1.32% of the samples had TG levels ≥ 400 mg/
dL, 22.3% had LDL-C values < 100 mg/dL, and 0.52% had LDL-C levels ≥ 220 mg/dL; in the KOICA (ranges, 
Figure 1.  Flowchart of study design. N number; HDL-C high-density lipoprotein cholesterol; Non-HDL-C 
non-high-density lipoprotein cholesterol; TC total cholesterol; LDL-C low-density lipoprotein cholesterol; dLDL 
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Table 1.  Distribution of lipid parameters of the study populations. Values are presented as mean (standard 
deviation), median (interquartile range), or as number (%). SD standard deviation; n, number; HDL-C high-
density lipoprotein cholesterol; Non-HDL-C non-high-density lipoprotein cholesterol; TC total cholesterol; LDL-
C low-density lipoprotein cholesterol; dLDL direct LDL-C; TG triglyceride; GSHC Gangnam Severance Hospital 
Check-up; KOICA Korea Initiatives on Coronary Artery Calcification; FLDL LDL-C estimated by Friedewald’s 










Cases, n (%) 129,985 (100.00) 53,036 (40.80)
Male, n (%) 69,575 (53.53) 35,978 (67.84)
Age, year 9–201 54.42 (13.14) 53 (45–62) 9–201 49.1 (13.22) 47 (39–56)
HDL-C, mg/dL 29–622 143.89 (36.41) 142 (118–167) 38–622 167.32 (36.7) 170 (143–191)
Non-HDL-C, 
mg/dL 10–386 124.82 (32.4) 123 (102–146) 15–386 141.52 (35.67) 143 (116–166)
Direct LDL-C, 
mg/dL 77–696 198.31 (37.03) 196 (173–221) 77–696 216.42 (42.01) 219 (187–246)
TC, mg/dL 8–3271 127.4 (85.5) 105 (75–153) 23–3271 184.72 (105.97) 167 (122–217)
TG, mg/dL 9–201 54.42 (13.14) 53 (45–62) 9–201 49.1 (13.22) 47 (39–56)
Cases by TG range, n (%)
 0–400 mg/dL 128,271 (98.68) 51,322 (96.77)
 ≥ 400 mg/dL 1714 (1.32) 1714 (3.23)
 ≥ 600 mg/dL 422 (0.32) 422 (0.80)
Cases by LDL-C range, n (%)
 < 40 mg/dL 111 (0.09) 39 (0.07)
40– 100 mg/dL 28,842 (22.19) 6880 (12.97)
 ≥ 100 mg/dL 101,032 (77.73) 46,117 (86.95)
 ≥ 220 mg/dL 678 (0.52) 678 (1.29)
Estimated LDL-C values
 FLDL, mg/dL − 214.2 to 370.2 118.41 (33.37) 116.8 (95.6–139.6) − 214.2 to 370.2 130.38 (40.07) 131.4 (102–159.6)
 MLDL, mg/dL − 89.31 to 366.98 120.38 (32.13) 118.49 (97.92–140.86) − 89.31 to 366.98 136.3 (35.28)
137.38 (111.03–
161)




Cases, n (%) 47,126 (100.00) 25,265 (53.61)
Male, n (%) 35,835 (76.04) 20,281 (80.27)
Age, year 16–97 54.05 (8.88) 53 (48–59) 17–97 54.03 (8.53) 53 (48–59)
HDL-C, mg/dL 13–162 52.33 (13.11) 50 (43–60) 13–162 48.35 (12.68) 46 (39–55)
Non-HDL-C, 
mg/dL 31–437 144.8 (34.81) 143 (121–167) 31–437 157.55 (36.83) 158 (132–183)
Direct LDL-C, 
mg/dL 11–356 124.6 (31.34) 123 (103–145) 11–356 132.06 (35.1) 131 (106–159)
TC, mg/dL 73–450 197.13 (35.04) 196 (173–219) 73–450 205.9 (39.42) 206 (178–234)
TG, mg/dL 16–2309 133.4 (85.17) 113 (79–163) 20–2309 172.14 (97.75) 158 (109–208)
Cases by TG range, n (%)
 0–400 mg/dL 46,455 (98.58) 24,594 (97.34)
 ≥ 400 mg/dL 671 (1.42) 671 (2.66)
 ≥ 600 mg/dL 121 (0.26) 121 (0.48)
Cases by LDL-C range, n (%)
 < 40 mg/dL 45 (0.1) 28 (0.11)
 40–100 mg/dL 10,061 (21.35) 4768 (18.87)
 ≥ 100 mg/dL 37,020 (78.56) 20,469 (81.02)
 ≥ 220 mg/dL 178 (0.38) 178 (0.70)
Estimated LDL-C Values
 FLDL, mg/dL − 122.6 to 370.4 118.12 (32.6) 117 (96–139) − 122.6 to 370.4 123.12 (37.73) 121.2 (95.8–150.6)
 MLDL, mg/dL − 14.06 to 368 120.62 (31) 119.35 (99.35–140.24) − 14.06 to 368 128.43 (34.25) 127.23 (103.4–153)
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TG: 16–2309 mg/dL; LDL-C: 11–356 mg/dL) the corresponding percentages were 1.42%, 21.4%, and 0.38%, 
respectively.
Figure 2 shows the overall good correlations between the estimated LDL-C values (FLDL, MLDL, and SLDL) 
and dLDL levels. However, MLDL showed a slightly better fit with dLDL than FLDL or SLDL in both the study 
groups (slope, 0.94; RMSE = 11.45 mg/dL;  R2 = 0.88; vs Friedewald equation: slope, 0.88; RMSE = 13.66 mg/
dL;  R2 = 0.82; vs Sampson equation: slope, 0.91; RMSE = 12.36 mg/dL;  R2 = 0.85 in the GSHC) (slope, 0.97; 
RMSE = 9.20 mg/dL;  R2 = 0.91; vs Friedewald equation: slope, 0.91; RMSE = 10.42 mg/dL;  R2 = 0.89; vs Sampson 
equation: slope, 0.93; RMSE = 9.39 mg/dL;  R2 = 0.91 in the KOICA).
Similar results were shown within the dyslipidaemia populations (Supplementary Fig. S1); again, MLDL 
showed a better fit with dLDL than FLDL, and fit better or similarly to SLDL in both the study groups (slope, 
0.93; RMSE = 14.18 mg/dL;  R2 = 0.84; vs Friedewald equation: slope, 0.80; RMSE = 15.96 mg/dL;  R2 = 0.80; vs 
Sampson equation: slope, 0.86; RMSE = 14.84 mg/dL;  R2 = 0.83 in the GSHC) (slope, 0.98; RMSE = 10.21 mg/dL; 
 R2 = 0.92; vs Friedewald equation: slope, 0.88; RMSE = 11.17 mg/dL;  R2 = 0.90; vs Sampson equation: slope, 0.93; 
RMSE = 10.15 mg/dL;  R2 = 0.92 in the KOICA).
We compared the three equations with a single integrated index of accuracy by the calculation of the MAD 
from the dLDL value first divided into samples with high and lower TG levels (severe hypertriglyceridaemia: 
TG ≥ 400 mg/dL) and LDL-C (low LDL-C: LDL < 100 mg/dL) (Fig. 3), then across the spectrum of TG levels 
and LDL-C values (Fig. 4). All the results were again validated in the dyslipidaemia populations within both 
the study groups (Supplementary Figs. S2 and S3). Confidence intervals for calculated MADs are available in 
Supplementary Tables S2 and S3.
The MAD values for each database in entirety indicated the overall superiority of MLDL (MAD = 9.61 mg/
dL; vs Friedewald equation: MAD = 11.19 mg/dL; vs Sampson equation: MAD = 9.97 mg/dL in the GSHC) 
(MAD = 7.67 mg/dL; vs Friedewald equation: MAD = 9.54 mg/dL; vs Sampson equation: MAD = 7.82 mg/dL in 
the KOICA), closely followed by SLDL; FLDL showed the poorest results. Similar findings were observed in the 
dyslipidaemia populations in both the databases (MAD = 11.97 mg/dL; vs Friedewald equation: MAD = 15.58 mg/
dL; vs Sampson equation: MAD = 13.06 mg/dL in the GSHC) (MAD = 8.15 mg/dL; vs Friedewald equation: 
MAD = 11.55 mg/dL; vs Sampson equation: MAD = 8.85 mg/dL in the KOICA).
MLDL was generally associated with the lowest MADs across the full spectrum of TG levels, whether divided 
into severe hyper/non-hyper to moderate hypertriglyceridaemia samples or stratified by 100-mg/dL TG intervals 
(Figs. 3A and 4) (MADs for MLDL vs FLDL vs SLDL: TG < 400 mg/dL, 9.37 mg/dL vs 10.68 mg/dL vs 9.65 mg/
dL; TG ≥ 400 mg/dL, 26.91 mg/dL vs 49.77 mg/dL vs 33.99 mg/dL in the GSHC, respectively) (MADs for MLDL 
vs FLDL vs SLDL: TG < 400 mg/dL, 7.58 mg/dL vs 9.23 mg/dL vs 7.69 mg/dL; TG ≥ 400 mg/dL, 14.37 mg/dL vs 
31.29 mg/dL vs 16.84 mg/dL in the KOICA, respectively), followed closely by SLDL; FLDL showed the weakest 
concordance.
When stratified by LDL-C levels across the spectrum, MLDL and SLDL generally showed closely matched 
superior results, while FLDL showed much lower performance levels (Figs. 3B and 4) (MADs for MLDL vs FLDL 
vs SLDL: LDL-C < 100 mg/dL, 7.76 mg/dL vs 8.90 mg/dL vs 7.82 mg/dL; LDL-C ≥ 100 mg/dL, 10.13 mg/dL vs 
11.85 mg/dL vs 10.59 mg/dL in the GSHC, respectively) (MADs for MLDL vs FLDL vs SLDL: LDL-C < 100 mg/
dL, 6.82 mg/dL vs 8.96 mg/dL vs 6.87 mg/dL; LDL-C ≥ 100 mg/dL, 7.91 mg/dL vs 9.70 mg/dL vs 8.08 mg/dL in 
Figure 2.  Scatter plots showing the correlation of direct LDL-C values with estimated LDL-C values using 
the Friedewald, Martin/Hopkins, and Sampson equations. RMSE root mean square error; GSHC Gangnam 
Severance Hospital Check-up; KOICA Korea Initiatives on Coronary Artery Calcification; LDL-C low-density 
lipoprotein cholesterol; dLDL direct LDL-C; TG triglyceride.
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the KOICA, respectively). Similar results were observed in the dyslipidaemia populations for both the TG and 
LDL-C strata.
Sensitivity analysis of all computed results was performed after excluding lipid value outliers, and the results 
in entirety is presented in Supplementary File 2. The overall results were similar to the original analysis, and 
trends were shown in more clarity.
Discussion
This study aimed to conduct comparative analyses of the performance of a novel equation and other widely-used 
equations in LDL-C estimation (Sampson’s, Friedewald’s, and Martin’s equations) with a direct homogeneous 
assay using two large contemporary real-world cohorts of East Asians.
Figure 3.  Residual error plots for LDL-C by different equations. (a) Severe hyperTG/ TG < 400 mg/dL; 
(b) High/Low LDL-C. MAD mean absolute difference; RMSE root mean square error; LDL-C low-density 
lipoprotein cholesterol; dLDL direct LDL-C; TG triglyceride; GSHC Gangnam Severance Hospital Check-up; 
KOICA Korea Initiatives on Coronary Artery Calcification.
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Overall, we concluded that Martin’s equation accounts for a slightly more superior estimation of LDL-C 
in Korean adults, both in the general population as well as in people with dyslipidaemia. The new Sampson’s 
equation closely matches Martin’s equation in performance, while Friedewald’s equation showed the most dis-
cordant results. The Martin equation was advantageous throughout all LDL-C and TG strata, even at severe 
hypertriglyceridaemic levels.
LDL-C level optimisation is among the main targets in the prevention of ASCVD, and substantial progress has 
been made toward LDL-C quantification. Martin’s equation was considerably superior to Friedewald’s equation, 
especially under conditions of low LDL-C or elevated TG  levels9. The 2018 AHA/ACC/Multi-society Choles-
terol Guideline provided a Class IIa recommendation for the use of Martin’s equation in patients with LDL-C 
levels < 70 mg/dL2. Additionally, Martin’s equation has been further validated in LDL-C estimation by numer-
ous studies, when LDL-C levels < 70 mg/dL and TG levels are > 150 mg/dL6,8,12. However, both the Friedewald 
and Martin equations were developed and validated for patients with serum TG levels < 400 mg/dL; MLDL also 
remains imperfect, particularly in cases with severe  hypertriglyceridemia13. Sampson et al. recently developed 
a new method for the calculation of LDL-C using β-quantification LDL-C values and multiple least squares 
regressions analysis. Their equation was reported to have a particularly good performance level in patients with 
hypertriglyceridemia (TG levels up to 800 mg/dL) and/or low LDL-C levels, and to show similar or slightly higher 
accuracy values than the other equations in those with normal lipid  levels5.
Consistent with previous studies, our analyses showed that the Martin and Sampson equations are generally 
more accurate than Friedewald’s equation.
Interestingly, in our study, Martin’s equation had a slight advantage over Sampson’s equation spanning the 
whole range of TG levels, and the advantage grew progressively stronger with increasing TG, even at severe hyper-
triglyceridaemic levels up to 500 ~ 600 mg/dL. Sampson et al. also observed similar accuracy values between the 
equations but at TG levels lower than 400 mg/dL. On comparing the performance of the Martin and Sampson 
equations at different LDL-C levels, the results showed similar levels of superiority over Friedewald’s equation. 
Sampson et al. also showed similar accuracy values between the equations at low LDL-C levels; however, in their 
study, SLDL began gaining an advantage over MLDL at an LDL-C level of approximately 100 mg/dL and pro-
gressively increased at higher LDL-C levels, as observed by the MAD values. This discrepancy warrants further 
validation since the Sampson equation may substantially underestimate LDL-C at low levels, as commented by 
Martin et al.14.
Several possibilities, including multifactorial differences across ethnicities, such as those pertaining to genet-
ics or associated lifestyles may have contributed to our finding on the superiority of MLDL according to TG 
strata even at high TG levels, potentially explaining other minor discrepancies between the results of the study 
Figure 4.  Comparison of the mean absolute difference scores between direct LDL-C and different estimated 
LDL-C values for various TG and LDL-C levels. TG triglyceride; LDL-C low-density lipoprotein cholesterol; 
GSHC Gangnam Severance Hospital Check-up; KOICA Korea Initiatives on Coronary Artery Calcification.
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conducted by Sampson et al. and our study. The likeliest variable is the patient sample that was used in the deri-
vation of the new equation, which differed significantly from that employed in this study. Sampson et al. used 
18,715 lipid samples from 8656 patients, as collected at the US National Institutes of Health for the derivation 
and external validation of their equation in multiple US datasets. Additionally, their derivation database included 
higher TG and non-HDL-C levels than those in the general US population, including extremely high TG levels 
of up to 3162 mg/dL, with 14% of the samples showing TG levels higher than 400 mg/dL. Our two Korean-based 
databases comprised significantly lower percentages of TG levels ≥ 400 mg/dL (1.32% and 1.42%).
However, it is important to note that most widely accepted treatment guidelines or risk calculation tools 
(such as the Pooled Cohort Equation, criteria for metabolic syndrome, etc.) have been developed on the basis of 
Western (mainly European and North American) populations, as has Sampson’s equation. Several studies that 
validated the application of such recommendations in non-Western populations showed discrepant  results15–18. 
Major societies in medicine have begun voicing the need for exercising caution in the extension of the same 
guidelines to other populations without supporting  research19,20; most recently, for example, the 2018/2019 
ACC/AHA guidelines stated that race and ethnicity influence the risk of CVD and choice of treatment (Class 
IIa)3. Our study is significant in that, to the best of our knowledge, it is the first to validate Sampson’s equation 
in an East Asian population.
Growing evidence suggests that high TG levels (by reflecting the number of triglyceride-rich lipoproteins 
[TRLs] and their remnants) are independent risk factors for CVD, at low HDL-C levels or  otherwise16,21–26. TRLs 
are hydrolysed into remnant-like lipoprotein particles, which are considered as atherogenic as LDL-C and as 
being associated with  atherogenesis27. New epidemiological and genetic insights as well as in-vitro/animal stud-
ies suggest that TRLs are causal risk factors for low-grade inflammation, atherosclerosis, ASCVD, and all-cause 
mortality, as opposed to LDL-C, causing atherosclerosis without a significant inflammatory  component21,22,25,27. 
Furthermore, numerous studies have indicated that a high TG level in itself is associated with insulin resistance, 
obesity, diabetes, and ultimately metabolic syndrome, and when concurrent with low HDL-C, which is more com-
monly observed in East Asians, demonstrates a high degree of  atherogenicity28. Such associations generally appear 
consistently among diverse populations, but the relative strength of the correlations differ by race or  ethnicity29.
East Asians are known to have lower LDL-C levels and higher TG levels than North Americans and 
 Europeans19,20,30–32. Koreans show a strong tendency towards hypertriglyceridaemia development, weak LDL-C 
distribution, as well as significantly low HDL-C levels. Over the last two decades, Koreans’ TC and LDL-C levels 
have progressively increased (albeit still relatively lower than those among their Western counterparts), and the 
trend of high TG and low HDL-C levels have become significantly more  pronounced15,33. The reasons for this may 
be multi-faceted: (1) Korean dietary patterns are characterised by significantly higher carbohydrate levels and 
lower fat proportions than those in Western countries (as per the 2017 statistics provided by the Korean Centers 
for Disease Control and Prevention, the average Korean diet comprises 62.4% carbohydrates and 22.5% fat; the 
corresponding numbers in the US were 47.3% and 34.8%, respectively)34. The consumption of carbohydrates in 
the place of fats leads to decreases in the levels of LDL-C and HDL-C and increases in the level of  TG35, especially 
in terms of carbohydrate-rich foods that comprise a major proportion of a Korean’s diet; (2) Population-specific 
genetic factors may have a significant effect; large-scale genetic association studies over the past few years have 
been identifying new, independent, and/or population-specific lipid loci as well as evaluating potential gene-
environment interactions with the goal of creating more informed genetic risk models according to population 
 type36–38; and (3) Differences related to race/ethnicity, including lifestyle factors, not only in terms of diet but 
also including factors such as a relatively sedentary  culture15.
According to 2019 ESC/EAS guidelines, the level of plasma TG, in addition to LDL-C, should be assessed in 
individuals who may have a higher risk of ASCVD; East Asians, who have higher TG and lower LDL-C levels 
than Caucasians, may have underestimated ASCVD risk, leading to the erroneous conclusion of non-eligibility 
for prophylactic statin  treatment4,13,22. Moreover, recent studies performed in Asian populations showed that 
serum TG was a better predictor of CVD than LDL-C, suggesting the possibility of the stronger importance of 
hypertriglyceridaemia over LDL-C in Asians than in  Westerners16–18,24,29.
Thus, we conclude that Martin’s equation, which fits in a superior manner with dLDL across the wide spec-
trum of TG, may be the best equation for LDL-C level estimation and accurate ASCVD risk calculation in 
Korean adults both in the general population and those with dyslipidaemia. As there is no clear explanation 
to definitively verify the cause-effect of our findings, further validation using large databases of multiple race/
ethnicities are warranted, preferably in the form of longitudinal prospective observational studies or randomised 
controlled trials. Analyses with β-quantification LDL-C in samples with very high TG and/or very low LDL-C 
levels would seem essential.
Limitations and strengths. Our study has some limitations. First, we used direct homogenous assays 
instead of the β-quantification method, which is considered the gold standard for LDL-C  measurement2. The 
direct homogeneous methods have been reported to lack specificity for LDL-C, in some cases measuring up to 
20% of  VLDL39–41. However, our automated methods are well-suited to routine clinical application and have 
an assay precision generally within the level stated in NCEP  guidelines42. Additionally, compared to ultracen-
trifugation methods, which require specialised laboratories, direct homogenous assays are readily available for 
automatic analysis and are, therefore, widely implemented in Korea. The Committee of Clinical Practice Guide-
lines of the Korean Society of Lipid and Atherosclerosis generally recommends the use of direct assays at a TG 
level ≥ 400 mg/dL, except in cases requiring critical  accuracy43. In addition, 2019 EAS/ESC Guidelines acknowl-
edge that both homogenous enzymatic methods and ultracentrifugation for direct LDL-C measurement are use-
ful in such  settings4. Considering the real-world medical environment in Korea, our analyses using homogenous 
assays bear practical merit. Second, these findings are specific to the Korean population. Differences in race and 
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the related dietary patterns may have affected the results; further validation is needed to generalise these results 
to other races and  ethnicities44. Lastly, due to the limitation of medical history acquired through questionnaires, 
accurate information regarding use of lipid-lowering medications was limited. Further studies investigating 
potential differences between medicated populations are warranted.
However, our study has significant strengths: (1) in our analysis, we used two large contemporary real-world 
databases that adequately reflect the lipid distributions and characteristics of the average individual one would 
most commonly encounter in a clinical setting; (2) sensitivity analyses and validation were also performed in 
participants with dyslipidaemia, a population eligible for statin therapy and in which accurate LDL-C estima-
tions are more significant, as well as dual analyses both including and excluding lipid value outliers; and (3) to 
the best of our knowledge, our study is the first to validate Sampson’s equation and compare its effectiveness 
with that of direct LDL-C measurement in a large real-world cohort, as well as the first of its kind conducted in 
an East Asian population.
Conclusion
In conclusion, we validated and compared Sampson’s equation for LDL-C with the Martin and Friedewald equa-
tions in an East Asian population. Martin’s equation could be a cost-effective alternative to direct LDL-C meas-
urement, which may be readily adoptable in clinical laboratories, irrespective of the presence of dyslipidaemia.
In Korean adults, among whom the prevalence of mild-to-moderate hypertriglyceridaemia is relatively high, 
Martin’s equation may be the best method for the estimation of LDL-C. Further validation in other populations 
with β-quantification LDL-C are warranted.
Data availability
The data underlying this article is available upon reasonable request to the corresponding authors.
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